Doree Pharmaceutical won the exclusive agent of Puradoxole Tablets mainland China

Duorui Pharmaceutical announced that recently, the company and Purapharm Pharmaceutical Industry Co., Ltd. (hereinafter referred to as "Purapharm") signed the "Letrozole Tablets Agency Agreement". Purapharm entrusts the company to be responsible for the sales promotion and related services of the product in the Chinese mainland, and Party A shall not authorize any third party to sell the product in the Chinese mainland during the validity period of the agreement. The agency period is from the date of signing of the agreement to July 5, 2026.

The chairman of the company is Deng Yong. Deng Yong, male, born in March 1966, Chinese nationality, no right of permanent residence abroad, bachelor degree. From September 1988 to June 1993, he served as a resident physician in Jingzhou Central Hospital; From July 1993 to December 1996, he worked in Zhongnan Company, supply and marketing of pharmaceutical materials; From January 1997 to December 1999, he was a freelancer; From January 2000 to December 2000, he worked in Hubei Yikang Pharmaceutical Co., Ltd.; From January 2001 to April 2002, he served as the general manager of Hubei Qingshengtang Pharmaceutical Co., Ltd.; From May 2002 to June 2020, he served as the executive director and general manager of Bo Ruijia; From July 2013 to June 2020, he served as the general manager of Ban Ruijia; From May 2017 to May 2020, he served as the chairman of Hubei Duorui; From December 2017 to December 2018, he served as the chairman of Duorui Limited; From December 2018 to January 2020, he served as the chairman and general manager of Duorui Limited; Since February 2020, he has served as the chairman and general manager of Tibet Duorui.

This article is compiled by the Securities Star Data Center based on publicly available data and does not constitute investment opinions or suggestions, if you have any questions, please contact us.